| Literature DB >> 31774115 |
Youxu Leng1, Hairong Zhou2, Fanjing Meng3, Tian Tian4, Jianying Xu4, Fengjuan Yan2.
Abstract
Many researches were conducted to assess the association of vitamin E intake on the risk of ovarian cancer, with conflict results. The current meta-analysis of published observational studies aimed to investigate the effect of vitamin E intake on ovarian cancer risk. The summary relative risks (RRs) with corresponding 95% confidence intervals (CIs) were calculated to measure the effectiveness of vitamin E intake on ovarian cancer risk using a random-effects model. As a result, 14 studies including 4597 patients were identified. Eleven studies reported about total vitamin E intake, eight studies about vitamin E intake from food only and five studies about vitamin E intake from supplement only on the risk of ovarian cancer. Overall, the summary RRs on ovarian cancer risk was 0.95 (95%CIs = 0.78-1.16) in total vitamin E intake, 0.99 (95%CIs = 0.77-1.27) in vitamin E intake from food only and 0.82 (95%CIs = 0.54-1.25) in vitamin E intake from supplement only. Results in subgroup analyses by study design and geographic location were consistent with overall result. In conclusions, the findings of this meta-analysis suggested that high intake of vitamin E from food or vitamin E supplement had no significant effect on the risk of ovarian cancer.Entities:
Keywords: food; meta-analysis; ovarian cancer; supplement; vitamin E
Mesh:
Substances:
Year: 2019 PMID: 31774115 PMCID: PMC6928519 DOI: 10.1042/BSR20193311
Source DB: PubMed Journal: Biosci Rep ISSN: 0144-8463 Impact factor: 3.840
Figure 1Flow chart of meta-analysis for exclusion/inclusion of studies
Characteristics of each individual study included in our analysis
| Study, Year | Design | Age | Participants, Cases | Country | Source of vitamin E | Category | RR (95%CI) |
|---|---|---|---|---|---|---|---|
| Chang et al., 2007 | Cohort | <84 | 97,275, | United States | Total vitamin E intake | >207 versus ≤7 mg/d | 1.46(0.76–2.79) |
| Cramer et al., 2001 | PBCC | >50 | 1065, | United States | Total vitamin E intake | Q5 versus Q1 | 0.97(0.64–1.49) |
| Fairfield et al., 2001 | Cohort | 30–55 | 80,326, | United States | Total vitamin E intake | 327 IU/day versus 5 IU/day | 0.88(0.61–1.27) |
| Fleischauer et al., 2001 | HBCC | ≥18 | 419, | United States | Total vitamin E intake | >43.5 versus <11.0 mg/d | 0.59(0.30–1.15) |
| Gifkins et al., 2012 | PBCC | >21 | 595, | United States | Total vitamin E intake | >114.9 versus <21.7 mg/d | 1.03(0.59–1.78) |
| Kushi et al., 1999 | Cohort | 55–69 | 29,083, | United States | From food | >24.4 versus <6.2 mg/d | 0.91(0.56–1.48) |
| McCann et al., 2001 | HBCC | 20–87 | 1921, | United States | From food | >9.4 versus ≤4.9 mg/d | 0.58(0.38–0.88) |
| Pan et al. 2004 | PBCC | 20–76 | 2577, | Canada | From supplement | ≥10 years versus never | 0.49(0.30–0.81) |
| Salazar-Martinez et al., 2002 | HBCC | 20–79 | 713, | Mexico | Total vitamin E intake | ≥9.4 versus ≤6.3 mg/d | 1.60(0.88–2.95) |
| Silvera et al., 2006 | Cohort | 40–59 | 89,835, | Canada | Total vitamin E intake | >28 versus <17 mg/d | 1.24(0.85–1.82) |
| Terry et al. 2017 | PBCC | 20–79 | 1038, | United States | Total vitamin E intake | >25.8 versus <6.7 mg/d | 0.91(0.61–1.37) |
| Thomson et al., 2008 | Cohort | 50–79 | 133,614, | United States | Total vitamin E intake | >403.2 versus <7.4 mg/d | 1.22(0.89–1.66) |
| Tung et al., 2005 | PBCC | 45–75 | 1165, | United States | Total vitamin E intake | Q4 versus Q1 | 0.80(0.56–1.16) |
| Zhang et al., 2004 | HBCC | 18–75 | 906, | China | Total vitamin E intake | ≥38.55 versus ≤23.40 mg/d | 0.41(0.24–0.70) |
Abbreviations: CI, confidence intervals; HBCC, hospital-based case–control study; PBCC, population-based case–control study; RR, relative risk.
Figure 2The forest plot about total vitamin E intake, vitamin E intake from food and vitamin E intake from supplement on ovarian cancer risk
Figure 3Funnel plot for the analysis of publication bias between total vitamin E intake and ovarian cancer risk